Literature DB >> 18649399

A Europe-wide assessment of current medication choices in Huntington's disease.

Josef Priller, Daniel Ecker, Bernhard Landwehrmeyer, David Craufurd.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18649399     DOI： 10.1002/mds.22188

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  12 in total

1.  Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology.

Authors:  Melissa J Armstrong; Janis M Miyasaki
Journal:  Neurology       Date:  2012-07-18       Impact factor: 9.910

Review 2.  [Potentials and limits of aging cohort studies for geriatric psychiatry].

Authors:  M A Rapp; M Tschorn; T Supprian; C Thomas; S Kreisel; J Benninghoff; G Schumann; A Heinz
Journal:  Nervenarzt       Date:  2020-11-26       Impact factor: 1.214

Review 3.  Therapy development in Huntington disease: From current strategies to emerging opportunities.

Authors:  Audrey S Dickey; Albert R La Spada
Journal:  Am J Med Genet A       Date:  2017-12-08       Impact factor: 2.802

4.  Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Shujun Chen; Tianyu Liang; Tao Xue; Shouru Xue; Qun Xue
Journal:  Front Neurol       Date:  2021-05-13       Impact factor: 4.003

5.  An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington's Disease.

Authors:  Karen Anderson; David Craufurd; Mary C Edmondson; Nathan Goodman; Mark Groves; Erik van Duijn; Daniel P van Kammen; Lavonne Goodman
Journal:  PLoS Curr       Date:  2011-09-20

6.  State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.

Authors:  Jessie S Gibson; Daniel O Claassen
Journal:  Expert Opin Pharmacother       Date:  2021-02-08       Impact factor: 4.103

7.  Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohort.

Authors:  Gaëlle Désaméricq; Guillaume Dolbeau; Christophe Verny; Perrine Charles; Alexandra Durr; Katia Youssov; Clémence Simonin; Jean-Philippe Azulay; Christine Tranchant; Cyril Goizet; Philippe Damier; Emmanuel Broussolle; Jean-François Demonet; Graca Morgado; Laurent Cleret de Langavant; Isabelle Macquin-Mavier; Anne-Catherine Bachoud-Lévi; Patrick Maison
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.240

Review 8.  Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine Modulation.

Authors:  Claudia Rangel-Barajas; George V Rebec
Journal:  J Huntingtons Dis       Date:  2016-12-15

Review 9.  Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.

Authors:  Emma M Coppen; Raymund A C Roos
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

Review 10.  Novel targets for Huntington's disease: future prospects.

Authors:  Sarah L Mason; Roger A Barker
Journal:  Degener Neurol Neuromuscul Dis       Date:  2016-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.